AUSTIN, Texas, Aug. 01, 2017 -- Jones Energy, Inc. (NYSE:JONE) (“Jones Energy” or “the Company”) announced today the closing of its previously announced Arkoma Basin divestiture for $65 million, subject to customary closing adjustments.
Jonny Jones, founder, chairman and CEO said, “The sale of our Arkoma Basin properties is a significant catalyst in our deleveraging story. Jones Energy is now a pure play Anadarko Basin company and we are using proceeds from the sale to pay down debt and focus our attention on the Merge. I look forward to updating you with additional asset sales as they occur and updating you with details on our second quarter earnings later this week.”
2017 Second Quarter Earnings Release and Conference Call
The Company also announced today that it plans to release its second quarter 2017 financial and operational results on Thursday, August 3, 2017 after the market closes. In connection with the earnings release, Jones Energy will host a conference call for investors and analysts to discuss its results on Friday, August 4, 2017 at 10:30 a.m. ET (9:30 a.m. CT). The conference call can be accessed via webcast through the Investor Relations section of Jones Energy’s website, www.jonesenergy.com, or by dialing (833) 231-8272 (for domestic U.S.) or (647) 689-4117 (International) and entering conference code 56297957.
If you are not able to participate in the conference call, the webcast replay and a downloadable audio file will be available shortly following the call through the Investor Relations section of the Company’s website, www.jonesenergy.com.
About Jones Energy
Jones Energy, Inc. is an independent oil and natural gas company engaged in the development and acquisition of oil and natural gas properties in the Anadarko basin of Texas and Oklahoma. Additional information about Jones Energy may be found on the Company’s website at: www.jonesenergy.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. Without limiting the generality of the foregoing, forward-looking statements contained in this press release specifically include the expected use of proceeds from the transactions contemplated by the Arkoma Agreement, and the Company’s continued marketing of non-core assets. These statements are based on certain assumptions made by the Company based on management’s experience and perception of historical trends, current economic and market conditions, anticipated future developments and other factors believed to be appropriate. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements.
Any forward-looking statement speaks only as of the date on which such statement is made and the Company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.
Investor Contact: Page Portas, 512-493-4834 Investor Relations Associate Or Robert Brooks, 512-328-2953 Executive Vice President & CFO


FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Italy Fines Apple €98.6 Million Over App Store Dominance
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 



